Table 1.
Patients characteristics.
| Cohort A | Cohort B | |
|---|---|---|
| Number of patients | 233 | 47 |
| Median age (years) | 52 | 48 |
| Median follow-up (months) | 20.8 | 13.8 |
| Hormone receptor status | ||
| ER and/or PR positive | 133 (57.6%) | 23 (50,0%) |
| ER and PR negative | 98 (42.4%) | 23 (50,0%) |
| Unknown | 2 | 1 |
| Metastasis sites at diagnosis MBC | ||
| Bone | 121 (51.9%) | 24 (51.1%) |
| Brain | 18 (7.7%) | 4 (8.5%) |
| Liver | 114 (48.9%) | 20 (42.5%) |
| Lung | 94 (40.3%) | 23 (48,9%) |
| Soft tissuea | 106 (45.5%) | 21 (44.7%) |
| Other | 20 (8.6%) | 5 (10.6%) |
| HER2 status | ||
| HER2 3+ | 213 (91.8%) | 47 (100%) |
| HER2 2+ (FISH amplified) | 19 (8.2%) | 0 (−) |
ER estrogen receptor, PR progesterone receptor.
a
Soft tissue includes lymph nodes, skin, pleura, and peritoneum.